General Information of Drug (ID: DMMIHSO)

Drug Name
ENERGI-F701 Drug Info
Indication
Disease Entry ICD 11 Status REF
Alopecia ED70 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMMIHSO

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Acadesine DM1RMF5 Diabetic complication 5A2Y Phase 3 [3]
MB-11055 DM3RBJW Fatty liver disease DB92.Z Phase 2 [4]
Imeglimin DMMQFG2 Diabetic complication 5A2Y Phase 2 [5]
PXL-770 DMNSRY7 Non-alcoholic fatty liver disease DB92 Phase 2 [6]
O-304 DMXM34I Type 2 diabetes 5A11 Phase 2 [7]
IM156 DM4MY9C Solid tumour/cancer 2A00-2F9Z Phase 1 [8]
Phenformin DMQ52JG Diabetic complication 5A2Y Withdrawn from market [9]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole DMN9YOB Discovery agent N.A. Investigative [10]
PMID23639540C13a DMLXOAQ Discovery agent N.A. Investigative [11]
SU 6656 DMF1P6W Discovery agent N.A. Investigative [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
AMP-activated protein kinase (AMPK) TTLAFZV AAPK1_HUMAN; AAKB1_HUMAN; AAKG1_HUMAN Activator [2]

References

1 ClinicalTrials.gov (NCT03351322) ENERGI-F701 for Female Hair Loss Treatment. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Energenesis Biomedical.
3 Acadesine, an adenosine-regulating agent with the potential for widespread indications. Expert Opin Pharmacother. 2008 Aug;9(12):2137-44.
4 Antidiabetes and antiobesity effect of cryptotanshinone via activation of AMP-activated protein kinase.Mol Pharmacol.2007 Jul;72(1):62-72.
5 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032542)
6 Clinical pipeline report, company report or official report of Poxel SA.
7 Clinical pipeline report, company report or official report of Betagenon.
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9 Complementary regulation of TBC1D1 and AS160 by growth factors, insulin and AMPK activators. Biochem J. 2008 Jan 15;409(2):449-59.
10 Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47.
11 Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52.
12 The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.